ADAPALENE AND BENZOYL PEROXIDE Drug Patent Profile

When do Adapalene And Benzoyl Peroxide patents expire, and when can generic versions of Adapalene And Benzoyl Peroxide launch?

Adapalene And Benzoyl Peroxide is a drug marketed by Actavis Labs Ut Inc, Actavis Mid Atlantic, Alembic, Aurobindo Pharma Ltd, Encube, Glenmark Pharms Ltd, Padagis Israel, Sun Pharma Canada, and Zydus Pharms. and is included in eleven NDAs.

The generic ingredient in ADAPALENE AND BENZOYL PEROXIDE is adapalene; benzoyl peroxide. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the adapalene; benzoyl peroxide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adapalene And Benzoyl Peroxide

A generic version of ADAPALENE AND BENZOYL PEROXIDE was approved as adapalene; benzoyl peroxide by PADAGIS ISRAEL on January 23^rd, 2018.

Summary for ADAPALENE AND BENZOYL PEROXIDE

US Patents:	0
Applicants:	9
NDAs:	11
Finished Product Suppliers / Packagers:	11
Clinical Trials:	43
What excipients (inactive ingredients) are in ADAPALENE AND BENZOYL PEROXIDE?	ADAPALENE AND BENZOYL PEROXIDE excipients list
DailyMed Link:	ADAPALENE AND BENZOYL PEROXIDE at DailyMed

Recent Clinical Trials for ADAPALENE AND BENZOYL PEROXIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sun Pharmaceutical Industries, Inc.	PHASE1
University of Oklahoma	Phase 3
Treatment and Diagnostic Center of Private Enterprise "Asklepiy"	N/A

See all ADAPALENE AND BENZOYL PEROXIDE clinical trials

Pharmacology for ADAPALENE AND BENZOYL PEROXIDE

Drug Class

Retinoid

US Patents and Regulatory Information for ADAPALENE AND BENZOYL PEROXIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs Ut Inc	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	209641-001	Jun 22, 2022	AB	RX	No	No
Padagis Israel	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	205033-001	Jan 23, 2018	AB	RX	No	No
Aurobindo Pharma Ltd	ADAPALENE AND BENZOYL PEROXIDE	adapalene; benzoyl peroxide	GEL;TOPICAL	217384-001	Jul 22, 2026	AB	RX	No	No

Adapalene and Benzoyl Peroxide Market Dynamics, Patent Exclusivity, and Financial Trajectory

Last updated: September 7, 2026

Adapalene and benzoyl peroxide is a mature topical acne combination with limited standalone revenue disclosure, substantial generic exposure, and continuing commercial relevance through prescription and consumer channels. The principal branded products are Galderma’s Epiduo and Epiduo Forte. The U.S. market has shifted from innovation-led growth to lifecycle management, generic price competition, and differentiation through concentration, tolerability, packaging, and access.

Epiduo contains adapalene 0.1% and benzoyl peroxide 2.5%. Epiduo Forte contains adapalene 0.3% and benzoyl peroxide 2.5%. Both are topical prescription products for acne vulgaris. Adapalene 0.1% is also available over the counter as Differin, while benzoyl peroxide is widely sold in prescription and nonprescription products.

What is the current market position of adapalene and benzoyl peroxide?

Adapalene and benzoyl peroxide occupies the combination-retinoid segment of the acne market. Its principal clinical advantage is the use of two established mechanisms in one product: adapalene reduces abnormal follicular keratinization and inflammation, while benzoyl peroxide has antimicrobial activity and does not create the same bacterial-resistance concern associated with topical antibiotics.

Product	Active ingredients	U.S. strength	Route	U.S. status	Commercial owner
Epiduo	Adapalene / benzoyl peroxide	0.1% / 2.5%	Topical gel	Prescription	Galderma
Epiduo Forte	Adapalene / benzoyl peroxide	0.3% / 2.5%	Topical gel	Prescription	Galderma
Differin Gel	Adapalene	0.1%	Topical gel	OTC	Galderma
Generic adapalene/BPO	Adapalene / benzoyl peroxide	Generally 0.1% / 2.5%	Topical gel	Prescription, where approved	Multiple generic manufacturers
Separate adapalene and benzoyl peroxide	Single active products	Multiple strengths	Topical	OTC and prescription	Multiple manufacturers

The combination remains clinically relevant because dermatology guidelines commonly support topical retinoids and benzoyl peroxide as first-line acne treatments. The fixed-dose format improves treatment convenience and avoids prescribing two separate products. The economic advantage is weaker in mature markets because patients and physicians can substitute generic adapalene, generic benzoyl peroxide, or separate low-cost products.

How large is the adapalene and benzoyl peroxide market?

Public companies generally do not report Epiduo or Epiduo Forte sales separately. Galderma reports at the portfolio or business-line level, which prevents a reliable standalone revenue figure for adapalene and benzoyl peroxide.

Galderma reported total net sales of approximately CHF 4.1 billion in 2023 across injectable aesthetics, dermatological skincare, and therapeutic dermatology. Epiduo is part of the therapeutic dermatology portfolio but is not separately quantified in the company’s public financial reporting.[1]

The relevant market should therefore be assessed through commercial drivers rather than a precise product revenue series.

Market driver	Effect on adapalene/BPO economics
Large acne patient population	Supports durable volume
Generic availability	Reduces price and branded share
OTC adapalene access	Expands category awareness but competes with prescription Epiduo
Fixed-dose convenience	Supports prescribing and adherence
Higher-strength Epiduo Forte	Provides a lifecycle-management option
Retail pharmacy substitution	Increases generic pressure
Dermatology access constraints	Can shift treatment toward OTC products
Cosmetic and direct-to-consumer marketing	Benefits differentiated branded products
Low manufacturing complexity	Limits barriers to entry

Revenue has likely followed a conventional branded topical trajectory: rapid uptake after launch, expansion through physician adoption and formulary access, followed by price pressure after generic entry. The branded product can retain revenue through physician preference, patient familiarity, availability, and the higher-strength Epiduo Forte product, but it lacks the exclusivity profile of a biologic or complex injectable.

When did Epiduo and Epiduo Forte lose exclusivity?

Epiduo received U.S. Food and Drug Administration approval in December 2008. It was a combination product based on previously known active ingredients, so its regulatory exclusivity was materially shorter than the commercial life of the product.[2]

Epiduo Forte was approved in July 2015. Its 0.3% adapalene concentration created a new prescription strength, but it did not reset exclusivity for the entire adapalene and benzoyl peroxide category.[3]

U.S. exclusivity timeline

Milestone	Date	Commercial significance
Epiduo U.S. approval	December 2008	Established the fixed-dose combination
Differin 0.1% OTC switch	2016	Expanded consumer access to adapalene
Epiduo Forte U.S. approval	July 2015	Added 0.3% adapalene strength
Generic combination competition	Post-branded exclusivity period	Increased pharmacy substitution and price pressure
Galderma IPO	March 2024	Improved public visibility into the company, but not standalone Epiduo sales

The key point is that regulatory exclusivity and patent protection are different. FDA exclusivity may have ended years before later formulation or manufacturing patents expired. A generic applicant can also challenge listed patents before those patents expire through an ANDA Paragraph IV certification.

What patents protect adapalene and benzoyl peroxide?

The patent estate has historically focused on the following areas:

1. Fixed-dose compositions containing adapalene and benzoyl peroxide.
2. Stabilization of the combination, because benzoyl peroxide is chemically reactive and adapalene can degrade under unsuitable formulation conditions.
3. Gel vehicles and excipient systems.
4. Manufacturing processes that produce a stable, uniform topical product.
5. Concentration-specific products, including higher-strength adapalene formulations.
6. Method-of-use claims covering acne treatment.

The most commercially relevant protection is usually the formulation and stability estate rather than basic composition-of-matter protection. Adapalene and benzoyl peroxide are old, established active ingredients. Their underlying molecule-level protection does not provide a durable barrier to generic competition.

Why formulation patents matter

A combination of a retinoid and benzoyl peroxide creates technical formulation challenges. Benzoyl peroxide can oxidize susceptible ingredients, while topical gels must maintain uniform dosing, acceptable skin feel, physical stability, and product shelf life.

Formulation patents can delay generic substitution when they claim a specific stabilizer system, polymer network, particle distribution, manufacturing sequence, or validated stability profile. Their practical strength depends on claim scope, prior art, infringement evidence, and whether an ANDA product uses the claimed formulation.

The strongest remaining commercial barriers are therefore likely to be:

• stable co-formulation technology;
• proprietary excipient combinations;
• manufacturing know-how;
• device or packaging controls;
• brand recognition and physician familiarity.

The weaker barriers are the active ingredients themselves and standard topical-gel manufacturing.

What is the Orange Book status of Epiduo?

Epiduo and Epiduo Forte are prescription drug products subject to FDA Orange Book analysis. Orange Book listings can include patents claiming the drug substance, drug product, or approved method of use. The relevant listing status can change as patents expire, are delisted, or are challenged.[4]

For commercial diligence, the critical questions are:

Orange Book issue	Implication
Listed formulation patent	May delay approval or trigger Paragraph IV litigation
Method-of-use patent	May permit a skinny-label strategy if claims are separable
Expired patent	No longer blocks approval, although other patents may remain
Patent dispute	Can create a 30-month stay under the Hatch-Waxman framework
No remaining blocking patent	Generic approval may proceed subject to FDA review
REMS or distribution restriction	Not a material barrier for standard Epiduo products

Because Epiduo is a topical combination product, the regulatory and technical review may be more complex than a simple oral generic. FDA must evaluate active-ingredient sameness, formulation equivalence, product performance, and bioequivalence requirements applicable to topical products.

Which companies are challenging or competing with Galderma?

Competition comes from three groups: generic manufacturers, branded prescription dermatology companies, and consumer-health companies.

Generic competitors

Generic manufacturers may compete with adapalene/BPO combination gels or with the individual ingredients. Likely commercial participants include large generic companies and topical dermatology specialists with established pharmacy distribution. The precise competitive set varies by country, product strength, and FDA approval status.

Generic entry creates two forms of pressure:

• direct substitution for Epiduo;
• substitution with separate adapalene and benzoyl peroxide products.

The second form is especially important because a patient can recreate the treatment regimen without purchasing the branded fixed-dose product.

Branded prescription competitors

The principal branded alternatives include:

• tretinoin products;
• tazarotene products;
• trifarotene products;
• clindamycin and benzoyl peroxide combinations;
• dapsone gel;
• azelaic acid;
• oral and topical antibiotic regimens;
• oral isotretinoin for severe disease.

Galderma’s Differin OTC product also competes indirectly with Epiduo by offering adapalene without a prescription. This expands brand presence but can cannibalize some lower-severity prescription demand.

What Paragraph IV risks exist for Epiduo?

Paragraph IV litigation risk depends on whether a generic applicant certifies that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For Epiduo, a Paragraph IV case would likely focus on formulation, stability, process, or method-of-use claims rather than the basic active ingredients.

The commercial scenarios are:

Generic strategy	Likely effect
Paragraph III certification	Entry after patent expiration
Paragraph IV certification	Potential early entry, litigation, and 30-month stay
Section viii statement	Omission of patented indications where legally available
Formulation redesign	Avoidance of asserted claims, potentially with development cost
Authorized generic	Preserves volume while reducing third-party substitution

A Paragraph IV challenge can accelerate market entry but also reduce generic economics if the applicant must develop a technically distinct formulation or defend a stability-based patent case.

No biosimilar pathway applies. Epiduo is a small-molecule topical drug, not a biologic. Competition proceeds through the ANDA or applicable national generic pathway rather than the U.S. biosimilar framework.

What is the financial trajectory for Galderma and Epiduo?

Epiduo is strategically important as a durable dermatology product, but it is unlikely to be a major standalone earnings driver for Galderma compared with injectable aesthetics, skincare brands, or higher-growth prescription products.

The financial trajectory has four phases:

Launch and adoption

Epiduo introduced a convenient combination format and benefited from the established clinical use of both active ingredients. Early revenue was supported by branded prescribing and the absence of direct fixed-dose generic competition.

Lifecycle expansion

Galderma added Epiduo Forte in 2015. The higher adapalene concentration created a product-segmentation strategy, allowing physicians to move selected patients to a stronger branded product while preserving the original formulation for other patients.

Generic erosion

Once generic combination products and low-cost component substitutes became available, branded price realization declined. Volume may remain durable, but net sales depend on payer coverage, copay support, physician prescribing, and pharmacy substitution rates.

Mature portfolio monetization

In the mature phase, the product generates cash flow through established demand, low incremental promotional requirements, and global distribution. Growth is more likely to come from geographic expansion, pricing, channel management, or line extensions than from unit growth in the United States.

Galderma’s 2024 public-market listing increased investor scrutiny of its prescription portfolio, but the company has not disclosed sufficient product-level data to isolate Epiduo’s annual revenue, gross margin, or contribution to adjusted EBITDA.[1]

How strong is the patent estate for adapalene and benzoyl peroxide?

The patent estate is moderate for a mature topical combination and weak for the active ingredients.

Patent category	Relative strength	Reason
Adapalene composition of matter	Low	Old active ingredient
Benzoyl peroxide composition of matter	Low	Long-established ingredient
Fixed-dose combination	Moderate	Can protect product architecture
Stable formulation	Moderate to strong	Technical performance may be difficult to replicate
Manufacturing process	Moderate	Depends on claim specificity and evidence
Method of use	Low to moderate	May be avoidable through labeling
Higher-strength product	Moderate	Supports differentiation but does not block all alternatives
Packaging and device	Low to moderate	Usually narrower and easier to design around

The estate is more useful for delaying or complicating generic entry than for preserving long-term premium pricing. Generic manufacturers can often design around narrow process or excipient claims, although topical equivalence requirements can raise development costs.

What generic launch scenarios exist?

Three launch outcomes are commercially realistic.

First-filer launch

A first approved ANDA applicant with a successful Paragraph IV strategy may obtain 180-day generic exclusivity, subject to the governing statutory conditions. This creates a temporary period of elevated generic economics followed by broader competition.

Delayed multi-generic entry

If formulation patents or litigation delay approval, several manufacturers may enter near the same time after the relevant blocking patents expire. This produces rapid price compression and pharmacy substitution.

Authorized-generic or brand-preservation strategy

Galderma can defend volume through contracting, patient assistance, an authorized generic, or promotion of Epiduo Forte and other branded dermatology products. These measures generally preserve market share better than price alone, but they reduce net pricing.

How does Epiduo compare with separate adapalene and benzoyl peroxide products?

Attribute	Epiduo	Separate products
Convenience	Single application product	Two products and potentially two applications
Cost	Typically higher when branded	Usually lower with generic or OTC products
Dosing consistency	Controlled fixed combination	Depends on patient use
Substitution risk	High after generic entry	Already highly commoditized
Formulation differentiation	Greater	Limited
Adherence potential	Generally better	More variable
Payer vulnerability	Higher for branded product	Lower for low-cost products

The fixed-dose product has a clear adherence proposition, but the price gap can outweigh that benefit in mature markets. The commercial question is whether physicians and patients value convenience enough to resist substitution.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are real but not prohibitive. A manufacturer must control:

• benzoyl peroxide particle size and dispersion;
• adapalene uniformity;
• chemical stability;
• viscosity and spreadability;
• preservative and excipient compatibility;
• tube or pump compatibility;
• microbial quality;
• batch-to-batch potency;
• shelf-life performance.

The main intellectual-property risk is a formulation that appears clinically equivalent but falls within a valid, enforceable claim covering stabilization, excipients, or the manufacturing process. The main regulatory risk is failure to demonstrate the required equivalence for a semisolid topical product.

Geographic protection varies materially. U.S. Orange Book patents do not automatically determine European, Canadian, Japanese, or emerging-market entry. Patent families, supplementary protection certificates, national prosecution outcomes, and local data-exclusivity rules must be assessed country by country.

Key Takeaways

• Adapalene and benzoyl peroxide is a mature, globally relevant topical acne combination.
• Galderma’s Epiduo and Epiduo Forte are the principal branded products.
• Standalone product revenue is not publicly disclosed.
• Galderma reported approximately CHF 4.1 billion in total 2023 net sales, but Epiduo is not separately reported.
• The active ingredients have limited remaining patent value because both are well-established.
• Formulation, stability, manufacturing, and concentration-specific patents provide the principal competitive protection.
• Generic risk is high because manufacturers can challenge the fixed combination or substitute separate adapalene and benzoyl peroxide products.
• No biosimilar risk applies.
• Epiduo Forte is the main branded lifecycle-management vehicle.
• Long-term financial performance depends on volume retention, payer access, generic timing, and portfolio-level cross-selling rather than substantial price expansion.
• The product remains commercially durable but is unlikely to be a primary growth engine for Galderma.

FAQs

Is adapalene and benzoyl peroxide still a profitable drug combination?

Yes, but profitability is more likely to come from durable volume and low incremental manufacturing cost than from premium pricing. Generic competition limits branded net revenue.

Is Epiduo stronger than Differin?

Epiduo combines adapalene with benzoyl peroxide, while Differin contains adapalene alone. Epiduo Forte also contains a higher adapalene concentration than standard Differin. Product selection depends on acne severity, tolerability, and clinician judgment.

Can a generic replace Epiduo with separate products?

In practice, generic adapalene plus benzoyl peroxide can replicate the two active ingredients, but the products may differ in formulation, application, tolerability, and adherence. A fixed-dose generic combination is a closer substitute.

Does Epiduo have biosimilar competition?

No. Epiduo is a small-molecule topical drug. Its competitors enter through generic-drug pathways, not the biosimilar pathway.

What is the largest commercial risk to Epiduo?

The largest risk is sustained substitution by low-cost generic combination products and separate adapalene and benzoyl peroxide products. Narrow formulation patents may delay competition but are unlikely to preserve long-term exclusivity by themselves.

References

1. Galderma Group AG. (2024). Annual report 2023.
2. U.S. Food and Drug Administration. (2008). Epiduo approval letter and prescribing information.
3. U.S. Food and Drug Administration. (2015). Epiduo Forte approval letter and prescribing information.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. American Academy of Dermatology Association. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973.